$ELDN
Eledon Pharmaceuticals, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515182900 Filed on May 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.130M $2.740M $1.340M
YoY Change 110.07% 104.48% 42.55%
% of Gross Profit
Research & Development $5.855M $10.56M $3.556M
YoY Change 33.31% 196.93% 145.24%
% of Gross Profit
Depreciation & Amortization $10.00K $5.000K $4.000K
YoY Change 0.0% 25.0%
% of Gross Profit
Operating Expenses $8.982M $13.30M $4.892M
YoY Change 52.63% 171.87% 104.69%
Operating Profit -$8.982M -$13.30M -$4.892M
YoY Change 52.63% 171.87% 104.6%
Interest Expense $30.00K $40.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $50.00K
YoY Change
Pretax Income -$8.960M -$13.26M -$4.850M
YoY Change 53.16% 173.4% 102.93%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.957M -$13.26M -$4.847M
YoY Change 53.08% 173.57% 102.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$64.00M -$94.71M -$37.31M
COMMON SHARES
Basic Shares Outstanding 22.41M shares 22.38M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.20M $94.20M $27.00M
YoY Change 292.45% 248.89%
Cash & Equivalents $59.08M $94.16M $27.01M
Short-Term Investments $24.10M
Other Short-Term Assets $3.600M $2.200M $800.0K
YoY Change 500.0% 175.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $86.76M $96.33M $27.80M
YoY Change 299.8% 246.52%
LONG-TERM ASSETS
Property, Plant & Equipment $339.0K $73.00K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $45.00K $45.00K $200.0K
YoY Change -97.19% -77.5%
Total Long-Term Assets $654.0K $318.0K $200.0K
YoY Change -61.53% 59.0%
TOTAL ASSETS
Total Short-Term Assets $86.76M $96.33M $27.80M
Total Long-Term Assets $654.0K $318.0K $200.0K
Total Assets $87.41M $96.65M $28.00M
YoY Change 273.55% 245.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.704M $3.434M $800.0K
YoY Change 42.0% 329.25%
Accrued Expenses $2.943M $2.320M $1.900M
YoY Change 17.72% 22.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.647M $5.754M $2.700M
YoY Change 25.59% 113.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.00K
YoY Change
Total Long-Term Liabilities $13.00K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.647M $5.754M $2.700M
Total Long-Term Liabilities $13.00K $0.00 $0.00
Total Liabilities $4.660M $5.754M $2.700M
YoY Change 25.95% 113.11%
SHAREHOLDERS EQUITY
Retained Earnings -$108.6M -$99.61M
YoY Change
Common Stock $191.3M $22.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $82.75M $90.90M $25.30M
YoY Change
Total Liabilities & Shareholders Equity $87.41M $96.65M $28.00M
YoY Change 273.55% 245.18%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$8.957M -$13.26M -$4.847M
YoY Change 53.08% 173.57% 102.8%
Depreciation, Depletion And Amortization $10.00K $5.000K $4.000K
YoY Change 0.0% 25.0%
Cash From Operating Activities -$11.01M -$11.10M -$4.780M
YoY Change 103.14% 132.22% 68.31%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K $45.00K $12.00K
YoY Change 1300.0% 275.0%
Acquisitions
YoY Change
Other Investing Activities -$24.15M $0.00
YoY Change
Cash From Investing Activities -$24.29M -$50.00K -$10.00K
YoY Change 242800.0% 400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.0K 60.00K 50.00K
YoY Change -150.0% 20.0% -266.67%
NET CHANGE
Cash From Operating Activities -11.01M -11.10M -4.780M
Cash From Investing Activities -24.29M -50.00K -10.00K
Cash From Financing Activities 220.0K 60.00K 50.00K
Net Change In Cash -35.08M -11.09M -4.740M
YoY Change 497.61% 133.97% 65.16%
FREE CASH FLOW
Cash From Operating Activities -$11.01M -$11.10M -$4.780M
Capital Expenditures -$140.0K $45.00K $12.00K
Free Cash Flow -$10.87M -$11.15M -$4.792M
YoY Change 100.92% 132.58% 68.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22413594 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27014000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22396540 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22396540 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
173018331 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5754000
CY2015Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
22000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3434000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99611000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2320000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
90896000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96650000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190485000
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
397000
CY2015Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q1 us-gaap Liabilities
Liabilities
5754000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
305000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94162000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2170000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2015Q1 us-gaap Assets
Assets
96650000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
96332000
CY2015Q1 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1518000
CY2013Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31753000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22382340 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22382340 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
173018331 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4243000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
765000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86351000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3478000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
103501000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107744000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
189830000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
497000
CY2014Q4 us-gaap Liabilities
Liabilities
4243000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
963000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105256000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33272000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2255000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2014Q4 us-gaap Assets
Assets
107744000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
107511000
CY2014Q4 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1853000
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
14860173 shares
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
14860173 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4776000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
495049 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.79
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16187604 shares
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2014Q1 us-gaap Allowance For Loan And Lease Losses Adjustments Net
AllowanceForLoanAndLeaseLossesAdjustmentsNet
45000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
344000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4892000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4847000
CY2014Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
45000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90000
CY2014Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
98000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
4892000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3556000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4739000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014Q1 us-gaap Depreciation
Depreciation
4000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
49000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-432000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2014Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
106000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1336000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
798000
CY2014Q1 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
45000
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
TOKAI PHARMACEUTICALS INC
CY2015Q1 dei Trading Symbol
TradingSymbol
TKAI
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11104000
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22384233 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.00 pure
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2168027 shares
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015Q1 us-gaap Allowance For Loan And Lease Losses Adjustments Net
AllowanceForLoanAndLeaseLossesAdjustmentsNet
34000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-85000
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
45000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13300000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-13260000
CY2015Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
40000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
634000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
13300000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10559000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11094000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Depreciation
Depreciation
5000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
55000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1158000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-45000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
CY2015Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
306000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2741000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2669000
CY2015Q1 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
34000
CY2015Q1 tkai Increase Decrease In Deferred Tax Assets
IncreaseDecreaseInDeferredTaxAssets
5000000
CY2015Q1 tkai Earliest Year Open For Tax Examination
EarliestYearOpenForTaxExamination
2011

Files In Submission

Name View Source Status
0001193125-15-182900-index-headers.html Edgar Link pending
0001193125-15-182900-index.html Edgar Link pending
0001193125-15-182900.txt Edgar Link pending
0001193125-15-182900-xbrl.zip Edgar Link pending
d900300d10q.htm Edgar Link pending
d900300dex101.htm Edgar Link pending
d900300dex311.htm Edgar Link pending
d900300dex312.htm Edgar Link pending
d900300dex321.htm Edgar Link pending
d900300dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkai-20150331.xml Edgar Link completed
tkai-20150331.xsd Edgar Link pending
tkai-20150331_cal.xml Edgar Link unprocessable
tkai-20150331_def.xml Edgar Link unprocessable
tkai-20150331_lab.xml Edgar Link unprocessable
tkai-20150331_pre.xml Edgar Link unprocessable